Severe community-acquired pneumonia (severe CAP) is a major cause of mortality. The REMAP-CAP Trial is a multi-centre randomised controlled platform trial utilising Bayesian adaptive methods for 4000 European and 2800 Australian and New Zealand ICU patients with severe CAP.
The STARRT-AKI Study will compare immediate initiation of RRT with a delayed approach to initiation of RRT for patients with severe AKI in ICU to assess the impact upon all-cause mortality at 90 days. 2,866 participants will be recruited globally, from over 100 sites throughout Australia, New Zealand, China, Canada, Europe, the United States and South America. The study population will consist of adult patients admitted to intensive care units with severe AKI who meet the full eligibility criteria for RRT.
STARRT-AKI is coordinated in collaboration with project originators Sean Bagshaw (University of Alberta) and Ron Wald (St Michael’s Hospital, University of Toronto) and the Applied Health Research Centre at St Michael’s Hospital in Toronto, Canada. The George Institute is a Regional Coordinating Centre, managing sites in Australia, New Zealand and China.
The TTM2 trial is an international, multicentre, parallel group, non-commercial, randomised, superiority trial in which a target temperature of 33°C after cardiac arrest will be compared with normothermia and early treatment of fever (Ø37.8°C) Patients eligible for inclusion will be unconscious adult patients with out-of-hospital cardiac arrest of a presumed cardiac cause with stable return of spontaneous circulation. Randomisation will be performed by a healthcare professional in the emergency department, in the angiography suite or in the intensive care unit via web-based application using permuted blocks with varying sizes, stratified by site. Due to the nature of the intervention, health care staff will not be blinded to the intervention. However, outcome assessors, prognosticators, statisticians and conclusion drawers will be blinded to group allocation.